Human methylome studies SRP286180 Track Settings
 
Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality [Adjacent Normal, Tumor]

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
CpG methylation ▾       PMD       AMR       HMR       CpG reads ▾      
Select subtracks by views and experiment:
 All views CpG methylation  PMD  AMR  HMR  CpG reads 
experiment
SRX9235358 
SRX9235359 
SRX9235360 
SRX9235361 
SRX9235362 
SRX9235363 
SRX9235364 
SRX9235365 
SRX9235366 
SRX9235367 
SRX9235368 
SRX9235369 
SRX9235370 
SRX9235371 
SRX9235372 
SRX9235373 
SRX9235374 
SRX9235375 
SRX9235376 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX9235358  CpG methylation  Tumor / SRX9235358 (CpG methylation)   Schema 
hide
 SRX9235358  HMR  Tumor / SRX9235358 (HMR)   Schema 
hide
 Configure
 SRX9235359  CpG methylation  Tumor / SRX9235359 (CpG methylation)   Schema 
hide
 SRX9235359  HMR  Tumor / SRX9235359 (HMR)   Schema 
hide
 Configure
 SRX9235360  CpG methylation  Tumor / SRX9235360 (CpG methylation)   Schema 
hide
 SRX9235360  HMR  Tumor / SRX9235360 (HMR)   Schema 
hide
 Configure
 SRX9235361  CpG methylation  Tumor / SRX9235361 (CpG methylation)   Schema 
hide
 SRX9235361  HMR  Tumor / SRX9235361 (HMR)   Schema 
hide
 Configure
 SRX9235362  CpG methylation  Tumor / SRX9235362 (CpG methylation)   Schema 
hide
 SRX9235362  HMR  Tumor / SRX9235362 (HMR)   Schema 
hide
 Configure
 SRX9235363  CpG methylation  Tumor / SRX9235363 (CpG methylation)   Schema 
hide
 SRX9235363  HMR  Tumor / SRX9235363 (HMR)   Schema 
hide
 Configure
 SRX9235364  CpG methylation  Tumor / SRX9235364 (CpG methylation)   Schema 
hide
 SRX9235364  HMR  Tumor / SRX9235364 (HMR)   Schema 
hide
 Configure
 SRX9235365  CpG methylation  Tumor / SRX9235365 (CpG methylation)   Schema 
hide
 SRX9235365  HMR  Tumor / SRX9235365 (HMR)   Schema 
hide
 Configure
 SRX9235366  CpG methylation  Tumor / SRX9235366 (CpG methylation)   Schema 
hide
 SRX9235366  HMR  Tumor / SRX9235366 (HMR)   Schema 
hide
 Configure
 SRX9235367  CpG methylation  Tumor / SRX9235367 (CpG methylation)   Schema 
hide
 SRX9235367  HMR  Tumor / SRX9235367 (HMR)   Schema 
hide
 Configure
 SRX9235368  CpG methylation  Tumor / SRX9235368 (CpG methylation)   Schema 
hide
 SRX9235368  HMR  Tumor / SRX9235368 (HMR)   Schema 
hide
 Configure
 SRX9235369  CpG methylation  Tumor / SRX9235369 (CpG methylation)   Schema 
hide
 SRX9235369  HMR  Tumor / SRX9235369 (HMR)   Schema 
hide
 SRX9235370  HMR  Tumor / SRX9235370 (HMR)   Schema 
hide
 Configure
 SRX9235370  CpG methylation  Tumor / SRX9235370 (CpG methylation)   Schema 
hide
 Configure
 SRX9235371  CpG methylation  Tumor / SRX9235371 (CpG methylation)   Schema 
hide
 SRX9235371  HMR  Tumor / SRX9235371 (HMR)   Schema 
hide
 Configure
 SRX9235372  CpG methylation  Tumor / SRX9235372 (CpG methylation)   Schema 
hide
 SRX9235372  HMR  Tumor / SRX9235372 (HMR)   Schema 
hide
 SRX9235373  HMR  Adjacent Normal / SRX9235373 (HMR)   Schema 
hide
 Configure
 SRX9235373  CpG methylation  Adjacent Normal / SRX9235373 (CpG methylation)   Schema 
hide
 Configure
 SRX9235374  CpG methylation  Adjacent Normal / SRX9235374 (CpG methylation)   Schema 
hide
 SRX9235374  HMR  Adjacent Normal / SRX9235374 (HMR)   Schema 
hide
 Configure
 SRX9235375  CpG methylation  Adjacent Normal / SRX9235375 (CpG methylation)   Schema 
hide
 Configure
 SRX9235376  CpG methylation  Adjacent Normal / SRX9235376 (CpG methylation)   Schema 
    

Study title: Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality
SRA: SRP286180
GEO: GSE158927
Pubmed: 36178085

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX9235358 Tumor 0.700 10.2 30405 1102.6 16721 1385.0 47 80214.7 0.954 title: GSM4815811 139C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "lethal"}
SRX9235359 Tumor 0.745 16.8 42703 1253.0 40708 2821.6 1190 397276.1 0.957 title: GSM4815812 1601C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "lethal"}
SRX9235360 Tumor 0.712 10.3 31966 1122.0 15812 1315.7 72 61194.4 0.960 title: GSM4815813 349C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "lethal"}
SRX9235361 Tumor 0.704 7.8 27346 1216.0 7653 1255.7 4 162126.2 0.939 title: GSM4815814 379C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "lethal"}
SRX9235362 Tumor 0.728 10.3 37098 1849.6 22290 3247.2 961 664744.0 0.954 title: GSM4815815 46C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "lethal"}
SRX9235363 Tumor 0.675 11.8 61441 2534.0 14637 2686.4 1289 630884.2 0.968 title: GSM4815816 514C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "lethal"}
SRX9235364 Tumor 0.649 8.6 26661 1373.7 6645 1230.2 381 1333734.4 0.930 title: GSM4815817 564C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "lethal"}
SRX9235365 Tumor 0.668 10.8 27542 1117.0 14380 1324.5 34 105100.1 0.964 title: GSM4815818 120C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235366 Tumor 0.725 11.3 29907 1024.6 17341 1341.1 70 50731.4 0.949 title: GSM4815819 1579C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235367 Tumor 0.642 10.9 35020 1208.9 25283 1651.9 133 51813.1 0.959 title: GSM4815820 174C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235368 Tumor 0.666 11.8 28746 1135.2 17356 1358.1 31 102820.7 0.967 title: GSM4815821 202C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235369 Tumor 0.731 8.1 26386 1214.5 13208 1462.4 518 1115947.8 0.948 title: GSM4815822 34C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235370 Tumor 0.606 11.2 28952 1230.1 14246 1371.9 41 128574.4 0.933 title: GSM4815823 361C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235371 Tumor 0.651 11.0 31018 1212.5 37744 2247.5 810 746778.7 0.956 title: GSM4815824 506C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235372 Tumor 0.763 10.9 38209 1060.9 18582 1375.1 114 41336.8 0.966 title: GSM4815825 5237C, Homo sapiens, Bisulfite-Seq; {"source_name": "Prostate tumour tissue", "tissue": "Tumour", "sex": "male", "patient_outcome": "non-lethal"}
SRX9235373 Adjacent Normal 0.573 9.6 25129 1350.7 4117 1226.4 24 1034346.9 0.927 title: GSM4815826 448N, Homo sapiens, Bisulfite-Seq; {"source_name": "Normal prostate tissue adjacent to tumour", "tissue": "Adjacent normal", "sex": "male", "patient_outcome": "NA"}
SRX9235374 Adjacent Normal 0.722 15.5 39592 1154.4 32830 1521.3 455 24490.9 0.955 title: GSM4815827 1601N, Homo sapiens, Bisulfite-Seq; {"source_name": "Normal prostate tissue adjacent to tumour", "tissue": "Adjacent normal", "sex": "male", "patient_outcome": "NA"}
SRX9235375 Adjacent Normal 0.624 7.4 22441 1349.1 2995 1163.3 11 631447.3 0.932 title: GSM4815828 564N, Homo sapiens, Bisulfite-Seq; {"source_name": "Normal prostate tissue adjacent to tumour", "tissue": "Adjacent normal", "sex": "male", "patient_outcome": "NA"}
SRX9235376 Adjacent Normal 0.612 7.9 23875 1350.1 3833 1207.7 13 559592.4 0.931 title: GSM4815829 508N, Homo sapiens, Bisulfite-Seq; {"source_name": "Normal prostate tissue adjacent to tumour", "tissue": "Adjacent normal", "sex": "male", "patient_outcome": "NA"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.